These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 16454541)

  • 1. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems.
    Carvajal A; Macias D; Sáinz M; Ortega S; Martín Arias LH; Velasco A; Bagheri H; Lapeyre-Mestre M; Montastruc JL
    Drug Saf; 2006; 29(2):143-9. PubMed ID: 16454541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
    Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
    Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.
    Conforti A; Magro L; Moretti U; Scotto S; Motola D; Salvo F; Ros B; Leone R
    Drug Saf; 2006; 29(12):1163-72. PubMed ID: 17147462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle rupture associated with statin use.
    Ekhart C; de Jong L; Gross-Martirosyan L; van Hunsel F
    Br J Clin Pharmacol; 2016 Aug; 82(2):473-7. PubMed ID: 27074553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
    Edwards IR; Star K; Kiuru A
    Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System.
    Carvajal A; Macias D; Gutiérrez A; Ortega S; Sáinz M; Martín Arias LH; Velasco A
    Drug Saf; 2007; 30(6):527-31. PubMed ID: 17536878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
    de Langen JJ; van Puijenbroek EP
    Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use.
    Fraunfelder FW; Richards AB
    Ophthalmology; 2008 Dec; 115(12):2282-5. PubMed ID: 18930555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins--the pattern of adverse effects with empahsis on mental reactions. Data from a national and an international database].
    Buajordet I; Madsen S; Olsen H
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3210-3. PubMed ID: 9411859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors.
    Fraunfelder FW
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):179-82. PubMed ID: 15117574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin-associated ocular disorders: the FDA and ADRAC data.
    Mizranita V; Pratisto EH
    Int J Clin Pharm; 2015 Oct; 37(5):844-50. PubMed ID: 25939673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
    Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
    Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
    Motola D; Vargiu A; Leone R; Conforti A; Moretti U; Vaccheri A; Velo G; Montanaro N
    Drug Saf; 2008; 31(7):609-16. PubMed ID: 18558794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
    Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle Damage Due to Fusidic Acid-Statin Interaction: Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports.
    Bataillard M; Beyens MN; Mounier G; Vergnon-Miszczycha D; Bagheri H; Cathebras P
    Am J Ther; 2019; 26(3):e375-e379. PubMed ID: 29189310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is decreased libido associated with the use of HMG-CoA-reductase inhibitors?
    de Graaf L; Brouwers AH; Diemont WL
    Br J Clin Pharmacol; 2004 Sep; 58(3):326-8. PubMed ID: 15327593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.
    Fernández AB; Karas RH; Alsheikh-Ali AA; Thompson PD
    Chest; 2008 Oct; 134(4):824-830. PubMed ID: 18689579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.